Physician profile
Sunil Bhat
NPI 1639391121
$2,321.90
in general payments reported to CMS, 2019-2025
35 companies · $32.53 in 2025
The $32.53 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $335 · 2021: $367 · 2022: $411 · 2023: $462 · 2024: $155 · 2025: $32.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $649.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $392.16 | 2019-2023 | Dovato |
| Gilead Sciences, INC. | $222.80 | 2019-2023 | |
| Brainlab, INC. | $205.96 | 2019 | |
| Merck Sharp & Dohme LLC | $181.75 | 2019-2023 | Dificid, Pifeltro, Delstrigo |
| Abbvie INC. | $172.95 | 2019-2024 | Viberzi, Linzess, Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $111.90 | 2022-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.25 | 2021-2023 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $78.75 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $72.85 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.16 | 2020-2023 | Stiolto Respimat |
| Exact Sciences Corporation | $65.54 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $57.26 | 2022-2023 | Spravato |
| Novo Nordisk INC | $54.92 | 2020-2025 | Ozempic |
| Janssen Biotech, INC. | $49.82 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $43.80 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $41.53 | 2021-2022 | |
| Pfizer INC. | $41.40 | 2020-2023 | |
| Mayne Pharma Commercial LLC | $35.50 | 2020 | |
| Emd Serono, INC. | $32.56 | 2019 | |
| Astellas Pharma US INC | $29.42 | 2020 | |
| Paratek Pharmaceuticals, INC. | $25.96 | 2020-2023 | Nuzyra |
| Abbott Laboratories | $22.63 | 2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $18.30 | 2023 | Voquezna |
| Theratechnologies INC. | $17.84 | 2021 | |
| Alkermes, INC. | $17.78 | 2024 | Aristada, Lybalvi |
| Esperion Therapeutics, INC. | $17.72 | 2024 | Nexletol |
| Cepheid | $17.31 | 2022 | |
| Cequr Corporation | $16.91 | 2024 | Cequr Simplicity |
| Biohaven Pharmaceuticals, INC. | $15.76 | 2021 | |
| Zealand Pharma US, INC. | $14.93 | 2022 | |
| Eisai INC. | $14.29 | 2021 | |
| Amarin Pharma, INC. | $13.90 | 2020 | |
| Xeris Pharmaceuticals, INC. | $13.87 | 2023 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $12.47 | 2021 | |
| Melinta Therapeutics, LLC | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.